EXHIBIT 16.1
April 24, 2002
Office of the Chief Accountant
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Dear Sir/Madam:
We have read the paragraphs 1, 2, 3 and 4 of Item 4 included in the Form 8-K dated April 25, 2002 of NeoTherapeutics, Inc. to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein.
Very truly yours,
/s/ Arthur Andersen LLP
Arthur Andersen LLP
cc: Mr. Sam Gulko, NeoTherapeutics, Inc.